Past, present and future of lupus nephritis.

IF 4 3区 医学 Q2 IMMUNOLOGY
Expert Review of Clinical Immunology Pub Date : 2026-02-01 Epub Date: 2026-03-03 DOI:10.1080/1744666X.2026.2637769
Claudio Ponticelli, Gabriella Moroni
{"title":"Past, present and future of lupus nephritis.","authors":"Claudio Ponticelli, Gabriella Moroni","doi":"10.1080/1744666X.2026.2637769","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Our objective is to delineate the evolution of lupus nephritis (LN) histological classifications and management, from their origins to the present histopathological framework and treatment strategies, and to consider prospective future directions.</p><p><strong>Areas covered: </strong>We describe the origins and progressive development of LN, particularly on histological classifications and pharmacological approaches to prevent renal disease progression and disease flares between 1950 and 2000 (the Past). Then, we discuss the remarkable advances achieved from 2001 to the present in the management, prognosis, and understanding of LN(the Present). Then, we envision a future shaped by the broader adoption of personalized medicine, the integration of novel biomarkers and artificial intelligence, and the innovative therapeutic strategies (the Future). Bibliography was searched in databases including PubMed, Medline, and Embase.</p><p><strong>Expert opinion: </strong>Despite improvement in LN diagnosis and management, many patients experience a poor quality of life and may progress to renal failure or die from complications often associated with immunosuppressive therapy. Future strategies are expected to make substantial contributions to the field of LN, including the identification of novel biomarkers, the application of artificial intelligence, the implementation of personalized medicine, and the development of innovative therapies improving long-term renal survival and patients' quality of life.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"195-209"},"PeriodicalIF":4.0000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2026.2637769","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Our objective is to delineate the evolution of lupus nephritis (LN) histological classifications and management, from their origins to the present histopathological framework and treatment strategies, and to consider prospective future directions.

Areas covered: We describe the origins and progressive development of LN, particularly on histological classifications and pharmacological approaches to prevent renal disease progression and disease flares between 1950 and 2000 (the Past). Then, we discuss the remarkable advances achieved from 2001 to the present in the management, prognosis, and understanding of LN(the Present). Then, we envision a future shaped by the broader adoption of personalized medicine, the integration of novel biomarkers and artificial intelligence, and the innovative therapeutic strategies (the Future). Bibliography was searched in databases including PubMed, Medline, and Embase.

Expert opinion: Despite improvement in LN diagnosis and management, many patients experience a poor quality of life and may progress to renal failure or die from complications often associated with immunosuppressive therapy. Future strategies are expected to make substantial contributions to the field of LN, including the identification of novel biomarkers, the application of artificial intelligence, the implementation of personalized medicine, and the development of innovative therapies improving long-term renal survival and patients' quality of life.

狼疮性肾炎的过去、现在和未来。
前言:我们的目的是描述狼疮性肾炎(LN)的组织学分类和管理的演变,从它们的起源到现在的组织病理学框架和治疗策略,并考虑未来的发展方向。区域覆盖。我们描述了LN的起源和逐步发展,特别是1950年至2000年间的组织学分类和预防肾脏疾病进展和疾病发作的药理学方法(过去)。然后,我们讨论了2001年至今在LN的管理、预后和理解方面取得的显著进展。然后,我们设想了一个由更广泛地采用个性化医疗、新型生物标志物和人工智能的整合以及创新治疗策略(未来)所塑造的未来。在PubMed、Medline和Embase等数据库中检索书目。专家意见:尽管LN的诊断和管理有所改善,但许多患者的生活质量很差,可能会发展为肾衰竭或死于免疫抑制治疗相关的并发症。未来的战略预计将对LN领域做出重大贡献,包括鉴定新的生物标志物,人工智能的应用,个性化医疗的实施,以及改善长期肾脏生存和患者生活质量的创新疗法的开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.60
自引率
2.30%
发文量
221
审稿时长
6-12 weeks
期刊介绍: Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书